🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT05865054
Recruiting Observational

Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)

NCT05865054 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2020-07-29
Last updated
2026-09-25

Condition(s) studied

Giant Cell Arteritis

Investigational drug(s) / intervention(s)

Magnetic Resonance Imaging (MRI)

Magnetic Resonance Imaging (MRI): Combined orbital and cranial vessel wall MRI

Study summary

The research study is being conducted to determine the utility of magnetic resonance imaging (MRI) in identifying inflammation of arteries supplying blood to the head, brain, and eyes. The target population includes patient with suspected giant cell arteritis (GCA; temporal arteritis).

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Age 50 years or older * First presentation of suspected GCA * New or worsening cranial manifestations within 4 weeks of enrollment concerning for active GCA * Elevated CRP greater than 1.0 mg/dl * Plan to undergo temporal artery biopsy or ultrasound for diagnosis Exclusion Criteria: * Contra-indication to receiving MRI including: Implanted medical devices, pacemaker, and metallic foreign fragments inside body/orbits Known gadolinium allergy Women who are pregnant or nursing * Absence of cranial symptoms related to GCA (e.g., only large vessel GCA)

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Mayo Building and Gonda Building Rochester Minnesota Recruiting
3400 Civic Center Blvd Philadelphia Pennsylvania Recruiting
St. Joseph's Healthcare Hamilton Hamilton Ontario Not Yet Recruiting
University Hospital Wuerzburg Würzburg Würzburg Not Yet Recruiting

More University of Pennsylvania trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05865054 on ClinicalTrials.gov ↗ ← All trials in Canada